Somatostatin Receptor Imaging May Establish the Neuroendocrine Nature of Unclarified Metastases by Pedersen, Kasper Tholstrup et al.
Syddansk Universitet
Somatostatin Receptor Imaging May Establish the Neuroendocrine Nature of
Unclarified Metastases
Pedersen, Kasper Tholstrup; Wilson, Benedicte Vibjerg; Simonsen, Jane Angel
Published in:
J M E D Research
DOI:
10.5171/2015.675765
Publication date:
2015
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Pedersen, K. T., Wilson, B. V., & Simonsen, J. A. (2015). Somatostatin Receptor Imaging May Establish the
Neuroendocrine Nature of Unclarified Metastases. J M E D Research, 2015, [675765]. DOI:
10.5171/2015.675765
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. aug.. 2017
IBIMA Publishing  
JMED Research 
http://www.ibimapublishing.com/journals/JMED/jmed.html  
Vol. 2015 (2015), Article ID675765, 3 pages  
DOI: 10.5171/2015.675765 
 
 
______________ 
 
Cite this Article as: Kasper Tholstrup Pedersen, Benedicte Vibjerg Wilson and Jane Angel Simonsen (2015), 
“Somatostatin Receptor Imaging May Establish the Neuroendocrine Nature of Unclarified Metastases”,  
JMED Research, Vol. 2015 (2015), Article ID 675765, DOI: 10.5171/2015.675765 
 
Research Article 
 
Somatostatin Receptor Imaging May 
Establish the Neuroendocrine Nature  
of Unclarified Metastases 
 
Kasper Tholstrup Pedersen
1
, Benedicte Vibjerg Wilson
2 
and Jane Angel Simonsen
3
 
 
1,2,3
Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark 
 
Correspondence should be addressed to: Kasper Tholstrup Pedersen; 
kasper.tholstrup.pedersen@rsyd.dk 
 
Received date: 20 August 2014; Accepted date: 20 October 2014; Published date: 28 December 2015 
 
Academic Editor: Renata Mikołajczak      
 
Copyright © 2015. Kasper Tholstrup Pedersen, Benedicte Vibjerg Wilson and Jane Angel Simonsen. 
Distributed under Creative Commons CC-BY 4.0  
 
Introduction 
 
Different imaging modalities may be of use 
in unclarified disease states. Positron 
emission tomography (PET) with F-18-
fluorodeoxyglucose (F-18-FDG) depicts 
cellular glucose metabolism with a high 
uptake being indicative of a high cellular 
turnover and, hence, consistent with on-
going infection, inflammation, or high grade 
malignancy (Hess, et al., 2014). Functional 
imaging with somatostatin analogues are 
used for visualizing neuroendocrine tumors 
(NETs) expressing somatostatin receptors 
due to their resemblance with normal 
neuroendocrine tissue. From time to time, 
imaging results may be atypical or even 
conflicting and, therefore, complicating the 
diagnostic process. Typically, however, 
different scans complement each other, and 
the right imaging techniques are useful not 
only for diagnostic purposes but also for 
revealing dissemination and guiding biopsy. 
This case illustrates the use of somatostatin 
receptor scintigraphy (SRS) with the 
somatostatin analogue 111In pentetreotide  
Abstract 
Traditionally, functional imaging with somatostatin receptor analogues is used in the primary 
diagnostics, staging, and monitoring of neuroendocrine tumors (NETs) as well as to assess the 
potential effect of treatment with (radioactive) somatostatin analogues. We report a case in 
which a woman was diagnosed with a low grade NET in a liver biopsy, but results from the 
diagnostic work-up pointed towards a synchronous, high grade, metastasizing malignancy. 
Because of the patient’s poor general health, invasive procedures were deemed unattainable. 
Somatostatin receptor scintigraphy with the tracer 111In-pentetreotide was therefore used as a 
very specific method of establishing the neuroendocrine nature of all the lesions found, and 
hence, palliative treatment could be commenced. This case thereby illustrates the feasibility of 
using somatostatin receptor imaging to establish the neuroendocrine nature of metastases 
suspected of originating from a synchronous high grade malignancy, when a low grade 
neuroendocrine tumor has been diagnosed elsewhere and invasive procedures are not possible. 
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(Octreoscan®) as a non-invasive means of 
establishing the neuroendocrine nature of 
metastases otherwise suspected to arise 
from a high grade malignancy, when 
invasive methods were not viable options. 
 
 Case 
 
A 70-year old woman was diagnosed with a 
3 cm inhomogeneous liver lesion, but did not 
attend a planned biopsy. An ultrasound 
examination after a year showed no growth 
of the lesion, and her case was terminated. 
Eight years later she presented with general 
discomfort, a 25 kg weight loss, fever,  
 
 
 
 
muscular pain, a raised erythrocyte 
sedimentation rate, and an elevated plasma 
concentration of C-reactive protein. A 
computed tomography (CT) of the chest and 
abdomen revealed multiple bone metastases 
throughout the skeleton, an atrophic left 
liver lobe, dilated hepatic ducts, and some 
enlarged retroperitoneal lymph nodes. A 
cholangiocarcinoma was suspected. A 
subsequent F-18-FDG PET/CT scan of the 
head, chest, and abdomen (Fig. 1) showed 
avid FDG uptake in the bone metastases, the 
known 3 cm lesion in a now atrophic left 
liver lobe, the right adrenal gland, the 
enlarged retroperitoneal lymph nodes, and 
near the head of the pancreas, supporting 
the diagnosis of cholangiocarcinoma.
 
 
 
Figure 1: FDG uptake in the bone metastases 
 
An ultrasound-guided biopsy from the liver 
lesion unexpectedly showed a metastasis 
from a NET positive in staining for 
synaptophysin, chromogranin A and CD56, 
but negative for CK7, CK20, CDX-2, and TTF-
1, and with a proliferation index (Ki-67) of 
1%. Because of the lack of organ-specific 
markers, the site of origin could not be 
determined histologically. A synchronous 
cancer giving rise to the numerous FDG-avid 
metastases was still suspected, but further 
invasive diagnostic procedures were 
undesirable due to the patient’s poor general 
condition. Because of its high specificity 
towards neuroendocrine tissue, a SRS with 
111In pentetreotide (Fig. 2) was performed 
showing increased uptake analogous to the 
FDG scan but in the right adrenal gland, 
which could not be distinctly separated from 
the liver. This was interpreted as evidence of 
the metastases being of neuroendocrine 
origin despite their avid FDG uptake. Since 
her general condition had deteriorated 
significantly, radiation therapy was 
commenced for pain relief only. She died a 
few months later. Autopsy was not 
performed. 
 
 
 
3                                                                                                                                                          JMED Research 
________________________________________________________________________________________________________________ 
______________ 
 
Kasper Tholstrup Pedersen, Benedicte Vibjerg Wilson and Jane Angel Simonsen (2015),  
DOI: 10.5171/2015.675765 
 
 
 
 
 
 
 
Figure 2: Increased uptake analogous to the FDG scan 
 
Discussion 
 
NETs originate from cells of the 
neuroendocrine system. NETs are 
subdivided into three grades based on their 
Ki-67 (Bosman, et al., 2010); grade 1, 2, and 
3 (G1, G2, and G3) with Ki-67 <2%, 2-20%, 
and >20%, respectively. Typically, the low 
grade NETs are well differentiated and 
express somatostatin receptors (SR) in 
abundance, whereas high grade NETs are 
often poorly differentiated and seldom 
express these receptors. SRS has a reported 
sensitivity of 50-100% towards identifying 
primaries and metastases from NETs 
depending on differentiation and thereby 
the degree of SR expression, with the lowest 
sensitivity for poorly differentiated NETs 
and insulinomas. Poorly differentiated NETs 
frequently show avid FDG uptake, whereas 
well differentiated NETs are rarely 
visualized by FDG PET attributed to their 
low rate of proliferation (Sundin, Garske and 
Orlefors, 2007). Furthermore, it has been 
found that 20-40% of all the diagnosed NETs 
were associated with a synchronous 
neoplasm, typically an adenocarcinoma 
(Modlin, Lye and Kidd, 2003), which should 
be kept in mind, if the diagnostic work-up 
does not “add up”. 
 
This case indicates a possible widening of 
the already established indications of SRS as 
it may sometimes be used to ascertain the 
nature of unclarified metastases when a G1 
NET has been diagnosed elsewhere and a 
synchronous cancer is suspected, but 
invasive procedures are not viable options. 
Furthermore, a G1 NET may show avid FDG 
uptake despite its low rate of proliferation, 
thereby possibly complicating the diagnostic 
process. 
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